Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double-Blind, Randomized, Placebo-Controlled Trial.

ABSTRACT:

Background

The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide may be beneficial in the regression of diabetic cardiomyopathy. South Asian ethnic groups in particular are at risk of developing type 2 diabetes.

Purpose

To assess the effects of liraglutide on left ventricular (LV) diastolic and systolic function in South Asian type 2 diabetes patients.

Study type

Prospective, double-blind, randomized, placebo-controlled trial.

Population

Forty-seven type 2 diabetes patients of South Asian ancestry living in the Netherlands, with or without ischemic heart disease, who were randomly assigned to 26-week treatment with liraglutide (1.8 mg/day) or placebo.

Field strength/sequence

3T (balanced steady-state free precession cine MRI, 2D and 4D velocit

SUBMITTER: Paiman EHM 

PROVIDER: S-EPMC7318583 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature